Benzinga | May 6, 2021 07:54AM EDT

Fulcrum Therapeutics Q1 EPS $(0.54) Beats $(0.66) Estimate, Sales $4.79M Beat $1.42M Estimate

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.66) by 18.18 percent. This is a 33.33 percent increase over losses of $(0.81) per share from the same period last year. The company reported quarterly sales of $4.79 million which beat the analyst consensus estimate of $1.42 million by 237.25 percent. This is a 538.53 percent increase over sales of $750.00 thousand the same period last year.